Lifecare Q2 2023 - MARD revealed and operational updates
2023-08-24 09:17:00
Redeye considers the financials of Lifecare’s Q2 2023 to be largely in line with estimates, as the deviation in absolute numbers is minor. Highlights from the quarters includes the presentation of a 9.6% MARD for Sencell, and a clearer picture of the development timeline.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/